Why the study?
Does LY122771-72 inhibit rhinovirus replication in human embryonic nasal organ cultures?
Does LY122771-72 inhibit rhinovirus replication in human embryonic nasal organ cultures?
LY122771-72 demonstrates potent in vitro antiviral activity against rhinovirus in human embryonic nasal organ cultures, supporting its potential evaluation in humans.
Answers are grounded in this paper and cite their sources.
LY122771-72 shows no immediate clinical utility; leaves open its therapeutic potential pending human trials.
The compound 2-amino-1-(isopropyl sulfonyl)-6-benzimidazole phenyl ketone oxime (LY122771-72) at a concentration of 0.2 microgram/ml completely inhibited rhinovirus replication in human embryonic nasal organ cultures, although in the absence of virus the compound did not inhibit ciliary activity when used at a concentration of 25 micrograms/ml. When added 26 hr after infection, the compound stopped rhinovirus production in organ cultures that had already started to release virus. Five rhinovirus types available for infection of volunteers and six recently obtained clinical isolates were shown to be more sensitive to LY122771-72 in tissue culture than the rhinovirus type 31 used in the organ culture experiments. These results suggest that this potential antiviral drgu should be evaluated in humans.
No takes yet. Share an insight, caveat, or question.
DeLong et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: